Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Investigation of nedaplatin and CpG oligodeoxynucleotide combination therapy in a mouse model of lung cancer

Jianfeng Quan, Yanli Zhao

Department of Oncology, The Affiliated Hospital of Shanxi University of Chinese Medicine, Weiyang Road, Xianyang, 712000, PR China;

For correspondence:- Yanli Zhao Email: yanli_z@yeah.net Tel:+862932087707

Accepted: 24 June 2018 Published: 28 July 2018

Citation: Quan J, Zhao Y. Investigation of nedaplatin and CpG oligodeoxynucleotide combination therapy in a mouse model of lung cancer. Trop J Pharm Res 2018; 17(7):1379-1384 doi: 10.4314/tjpr.v17i7.22

© 2018 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the anti-tumor effects of nedaplatin (NDP) and CpG oligodeoxynucleotide (CpG-ODN) combination therapy in a mouse-modeled lung cancer.

Methods: To evaluate the anti-tumor effects of NDP and CpG-ODN combination therapy, a lung cancer xenograft mouse model was established by subcutaneous injection of LA-795 cells. BALB/c mice were divided into four groups as follows: NDP, CpG-, NDP + CpG-ODN and untreated control group. The sections of lung cancer tissue were stained with hematoxylin and eosin (H&E) and morphologically examined. Spleen, body weight, and spleen index were measured. Flow cytometry was used to determine the proportions of CD3⁺, CD8⁺, CD4⁺ and CD4⁺/CD8⁺ in mice blood cells. Serum levels of interferon-γ (IFN-γ) and interleukin-12 (IL-12) were measured by enzyme-linked immunosorbent assay (ELISA).

Results: NDP + CpG-ODN therapy significantly reduced tumor volume and prolonged the survival time of tumor-bearing mice. NDP + CpG-ODN induced a change in cancer cell morphology, including large areas of necrosis which correlated with a reduction in tumor size. NDP + CpG-ODN significantly increased spleen weight/index and dramatically enhanced immune cell activation. This was evident in the increase serum levels of IFN-γ and IL-12.

Conclusion: NDP and CpG-ODN combination therapy inhibits the growth of lung cancer and prolongs the survival time of tumor-bearing mice. This may result from the activation of immune cells and increased expression of IFN-γ and IL-12.

Keywords: CpG ODN, NDP, Lung cancer, Combination therapy